Showing results (741-750 of 968) with videos related to
Sort By:
Pageof 97
Tropical Medicine & International Health : TM & IH|December 3, 1999
Foci of Schistosomiasis mekongi, Northern Cambodia: II. Distribution of infection and morbidityA H Stich, S Biays, P Odermatt, et al.Cellular and Molecular Life Sciences : CMLS|February 27, 2010
A 629RKLKK633 motif in the hinge region controls the androgen receptor at multiple levelsTamzin M Tanner, Sarah Denayer, Bart Geverts, et al.Movement Disorders : Official Journal of the Movement Disorder Society|May 25, 2007
Bowel movement frequency in late-life and incidental Lewy bodiesRobert D Abbott, G Webster Ross, Helen Petrovitch, et al.The Journal of Pediatrics|May 23, 2007
Nephropathy advancing to end-stage renal disease: a novel complication of lysinuric protein intoleranceLaura M Tanner, Kirsti Näntö-Salonen, Harri Niinikoski, et al.Journal of Clinical Lipidology|July 19, 2020
Low-density lipoprotein cholesterol levels among individuals experiencing statin-associated symptoms: Data from the REasons for Geographic And Racial Differences in Stroke (REGARDS) studyRikki M Tanner, Lisandro D Colantonio, Meredith L Kilgore, et al.Vaccine|February 1, 1994
A trial of the synthetic malaria vaccine SPf66 in Tanzania: rationale and designP L Alonso, M Tanner, T Smith, et al.The Lancet. Neurology|October 18, 2025
Environmental toxicants and Parkinson's disease: recent evidence, risks, and prevention opportunitiesE Ray Dorsey, Briana R De Miranda, Sarrah Hussain, et al.Journal of Clinical Psychopharmacology|November 6, 2019
A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive DyskinesiaStephen R Marder, Carlos Singer, Jean-Pierre Lindenmayer, et al.Parkinsonism & Related Disorders|June 5, 2012
Penetrance of LRRK2 G2385R and R1628P is modified by common PD-associated genetic variantsChaodong Wang, Yanning Cai, Zheng Zheng, et al.Movement Disorders : Official Journal of the Movement Disorder Society|August 24, 2017
Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3)Wolfgang Oertel, Karla Eggert, Rajesh Pahwa, et al.Pageof 97